posimir Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Posimir, and what generic alternatives are available?
Posimir is a drug marketed by Innocoll and is included in one NDA. There are six patents protecting this drug.
This drug has sixty-one patent family members in twenty-nine countries.
The generic ingredient in POSIMIR is bupivacaine. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bupivacaine profile page.
DrugPatentWatch® Generic Entry Outlook for Posimir
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 12, 2041. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for posimir?
- What are the global sales for posimir?
- What is Average Wholesale Price for posimir?
Summary for posimir
International Patents: | 61 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 125 |
Patent Applications: | 4,904 |
What excipients (inactive ingredients) are in posimir? | posimir excipients list |
DailyMed Link: | posimir at DailyMed |
![posimir drug patent expirations Drug patent expirations by year for posimir](/p/graph/s/t/posimir-patent-expirations.png)
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for posimir
Generic Entry Date for posimir*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION, EXTENDED RELEASE;INFILTRATION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for posimir
Drug Class | Amide Local Anesthetic |
Physiological Effect | Local Anesthesia |
US Patents and Regulatory Information for posimir
posimir is protected by six US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of posimir is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting posimir
Sustained release drug delivery systems with reduced impurities and related methods
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TO PRODUCE POST-SURGICAL ANALGESIA
Controlled delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Controlled delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS
Controlled delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS
Controlled delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS
FDA Regulatory Exclusivity protecting posimir
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Innocoll | POSIMIR | bupivacaine | SOLUTION, EXTENDED RELEASE;INFILTRATION | 204803-001 | Feb 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Innocoll | POSIMIR | bupivacaine | SOLUTION, EXTENDED RELEASE;INFILTRATION | 204803-001 | Feb 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Innocoll | POSIMIR | bupivacaine | SOLUTION, EXTENDED RELEASE;INFILTRATION | 204803-001 | Feb 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Innocoll | POSIMIR | bupivacaine | SOLUTION, EXTENDED RELEASE;INFILTRATION | 204803-001 | Feb 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Innocoll | POSIMIR | bupivacaine | SOLUTION, EXTENDED RELEASE;INFILTRATION | 204803-001 | Feb 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Innocoll | POSIMIR | bupivacaine | SOLUTION, EXTENDED RELEASE;INFILTRATION | 204803-001 | Feb 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Innocoll | POSIMIR | bupivacaine | SOLUTION, EXTENDED RELEASE;INFILTRATION | 204803-001 | Feb 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for posimir
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pacira Ireland Limited | Exparel liposomal | bupivacaine | EMEA/H/C/004586 Exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain.in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds. |
Authorised | no | no | no | 2020-11-16 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for posimir
When does loss-of-exclusivity occur for posimir?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Brazil
Patent: 2022013784
Patent: SISTEMAS DE DISTRIBUIÇÃO DE FÁRMACOS DE LIBERAÇÃO PROLONGADA COM IMPUREZAS REDUZIDAS E MÉTODOS RELACIONADOS
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 67217
Patent: SYSTEMES D'ADMINISTRATION DE MEDICAMENT A LIBERATION PROLONGEE AVEC IMPURETES REDUITES ET PROCEDES ASSOCIES (SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODS)
Estimated Expiration: ⤷ Sign Up
China
Patent: 5666621
Patent: 具有减少的杂质的持续释放药物递送系统及相关方法 (Sustained release drug delivery systems with reduced impurities and related methods)
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 90353
Patent: SYSTÈMES D'ADMINISTRATION DE MÉDICAMENT À LIBÉRATION PROLONGÉE AVEC IMPURETÉS RÉDUITES ET PROCÉDÉS ASSOCIÉS (SUSTAINED RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED METHODS)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 23515918
Patent: 不純物が低減された徐放性薬物送達システム及び関連の方法
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 220140711
Patent: 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering posimir around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | E032040 | ⤷ Sign Up | |
South Korea | 101351771 | ⤷ Sign Up | |
Croatia | P20120254 | ⤷ Sign Up | |
Japan | 5285374 | ⤷ Sign Up | |
Slovenia | 1809329 | ⤷ Sign Up | |
China | 101035562 | Sustained local anesthetic composition containing preferably a sugar ester such as saib | ⤷ Sign Up |
Lithuania | 2767292 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |